BSX — BOSTON SCIENTIFIC CORP

NYSE · Health Care · Health Care Equipment & Supplies · CIK 885725 ·
Last close
$45.60
Market Cap
$67.78B
52W High
$71.20
52W Low
$44.05
ADV30
21,197,721
Next earnings
2026-07-29
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 5,203,000,000 3,613,000,000 1,072,000,000 1,341,000,000 44,351,000,000 1,453,000,000 18,247,000,000
Dec 2025 5,286,000,000 3,678,000,000 1,041,000,000 672,000,000 43,673,000,000 1,965,000,000 19,201,000,000
Sep 2025 5,065,000,000 3,542,000,000 1,050,000,000 755,000,000 42,707,000,000 1,275,000,000 19,077,000,000
Jun 2025 5,061,000,000 3,424,000,000 943,000,000 797,000,000 41,559,000,000 534,000,000 18,906,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$4,341,000,000
Investing CF
$-2,730,000,000
Financing CF
$-889,000,000
CapEx
$-1,043,000,000
Dividends Paid
$0
Buybacks
EPS Diluted TTM
$2.39
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$6,912,000,000
Inventory
$3,117,000,000
Receivables
$3,027,000,000
ST Investments
EBIT TTM
$4,099,000,000
Pretax Income TTM
$3,742,000,000
Interest Exp TTM
$357,000,000
Analysts
32

Yahoo Snapshot (yfinance, live)

Total Revenue
$20,614,000,640
EBITDA
$5,500,000,256
Free Cash Flow
$2,807,124,992
Enterprise Value
$77,593,796,608
Total Cash
$1,452,999,936
Total Debt
$11,029,000,192
Shares Out
1,486,355,179
Trailing EPS
$2.39
Book Value
$17.40
ROE
14.7%
ROA
6.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 20,074,000,000 3,971,000,000 2,898,000,000 43,673,000,000 19,201,000,000 4,534,000,000
Dec 2024 16,747,000,000 3,002,000,000 1,854,000,000 39,395,000,000 17,392,000,000 3,435,000,000
Dec 2023 14,240,000,000 2,417,000,000 1,593,000,000 35,136,000,000 15,606,000,000 2,503,000,000
Dec 2022 12,682,000,000 2,034,000,000 698,000,000 32,469,000,000 14,896,000,000 1,526,000,000

TTM Snapshot

Revenues TTM
$13,838,000,000
NetIncome TTM
$1,553,000,000
OpCashFlow TTM
$0
Assets (Latest)
$39,395,000,000
Forward EPS
$3.72

Max Pain — expiry 2026-06-26

max pain strike: $46.00 · spot: $44.46 · call oi: 15,064 · put oi: 9,576
Expected Move to 2026-06-26: ±$1.32 (2.98%) — implied range $43.13$45.78 · ATM straddle on $44.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MMM 3M CO $84.41B $161.84
EW Edwards Lifesciences Corp $50.07B $86.95
MDT Medtronic plc $103.21B $80.63
BDX BECTON DICKINSON & CO $39.66B $143.92
SYK STRYKER CORP $118.84B $310.00

News headlines (Yahoo Finance, 1h cache)

How a Targeted Valve Recall and Watchman Questions at Boston Scientific (BSX) Have Changed Its Investment Story
2026-06-24 20:12 · Yahoo
Boston Scientific (BSX) Recalls Orca Valves Nationwide After Device Malfunction
2026-06-24 19:15 · Yahoo
Boston Scientific (BSX) Gains As Market Dips: What You Should Know
2026-06-23 22:15 · Yahoo
The Cash-Flow Fortress The Stryker Stock Bears Keep Missing
2026-06-23 18:11 · Yahoo
Piper Sandler Maintains Overweight Rating for Boston Scientific (BSX)
2026-06-23 15:06 · Yahoo
Jim Cramer on Boston Scientific: “This Whole Cohort Is Just Too Hard to Own”
2026-06-23 14:41 · Yahoo
Is Procedure Growth Broad-Based Enough to Support ISRG's 2026 Outlook?
2026-06-23 14:13 · Yahoo
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
2026-06-23 13:30 · Yahoo
This Undervalued Medical-Devices Stock Is Poised for a Rebound
2026-06-22 15:45 · Yahoo
Truist Cuts Boston Scientific (BSX) ’s Target as Doctors Change How They Use Its Heart Device
2026-06-22 14:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.